Kyntra Bio, Inc. expected to post a loss of $3.55 a share - Earnings Preview
Kyntra Bio, Inc. KYNB.O is expected to show a rise in quarterly revenue when it reports results on November 16 for the period ending September 30 2026
The San Francisco California-based company is expected to report a 64.1% increase in revenue to $1.766 million from $1.08 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Kyntra Bio, Inc. is for a loss of $3.55 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Kyntra Bio, Inc. is $38.00, about 958.5% above its last closing price of $3.59
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2026 | -3.14 | -3.18 | -4.69 | Missed | -47.3 |
Mar. 31 2026 | -3.28 | -3.35 | -3.76 | Missed | -12.1 |
Dec. 31 2025 | -3.88 | -3.61 | Beat | 7.1 | |
Sep. 30 2025 | -4.19 | -4.00 | -3.25 | Beat | 18.9 |
Jun. 30 2025 | -2.63 | -2.30 | -1.88 | Beat | 18.4 |
Mar. 31 2025 | 0.50 | 0.50 | 1.25 | Beat | 150 |
Dec. 31 2024 | -2.00 | -3.50 | 4.50 | Beat | 228.6 |
Sep. 30 2024 | -7.74 | -7.62 | -4.25 | Beat | 44.3 |
This summary was machine generated November 13 at 21:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)